Psilocybin for Anhedonia

This trial aims to determine if a single dose of psilocybin, a psychedelic compound, can improve anhedonia (loss of interest or pleasure) in individuals who continue to experience symptoms despite taking antidepressants like SSRIs or SNRIs. Researchers will compare psilocybin's effects to a placebo to assess its impact on brain function and mood. Individuals may qualify if they have major depressive disorder, experience emotional blunting, and have not fully responded to antidepressants. Participants must have no recent experience with psychedelics and must commit to multiple MRI sessions. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to be among the first to receive this innovative treatment.

The trial does not specify that you must stop taking your current prescription medications, but you must refrain from taking all non-prescription medications and supplements for at least 1 week before the psilocybin session unless approved by the Investigator.

Research has shown that psilocybin, the treatment under study, has been used safely in other clinical trials. Studies indicate that a single dose of psilocybin, combined with psychological support, can rapidly and lastingly reduce symptoms such as depression and suicidal thoughts. Most participants experience only mild side effects, like nausea or headaches, while serious side effects remain rare. It is important to note that psilocybin is still under investigation, and ongoing studies will continue to provide more safety information.¹²³⁴⁵

Psilocybin is unique because it taps into a novel mechanism of action, targeting serotonin receptors in the brain. Unlike traditional treatments for anhedonia, which often include antidepressants like SSRIs and therapy, psilocybin may rapidly enhance mood and emotional processing after just a single supervised dose. Researchers are excited about psilocybin's potential to offer fast-acting relief, providing hope for those who don't respond well to conventional treatments.

Studies have shown that psilocybin can improve symptoms of depression and a lack of interest or pleasure in activities, even when other treatments fail. One study revealed that patients with high levels of this lack of interest experienced significant improvements after psilocybin treatment. Research also indicates that the positive effects of psilocybin on depression and lack of interest can last for months. Another study found that psilocybin treatment led to a 75% response rate in patients, with 58% experiencing complete relief of symptoms for up to a year. These findings suggest that psilocybin holds promise for those dealing with difficult-to-treat symptoms. Participants in this trial will receive either psilocybin or a placebo to further evaluate its effectiveness.¹²³⁵⁶